Home/Research library/Ionescu & Frohman (2006)
Study in humans · 2006 · cited for CJC-1295 with DAC

Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog

Ionescu M, Frohman LA. The Journal of clinical endocrinology and metabolism 2006;91(12):4792-7. doi:10.1210/jc.2006-1702 · PubMed 17018654

In brief

Pulsatile release matters for growth hormone, and a long-acting stimulus might be expected to flatten it. This study measured growth hormone every 20 minutes through the night in healthy young men before and a week after one injection of CJC-1295. Secretion increased but pulsatility was preserved: the number and size of secretory pulses did not change. What changed was the floor. Trough growth hormone rose 7.5-fold, mean levels rose 46 percent and IGF-I rose 45 percent. The two doses studied gave similar results, and the size of the IGF-I rise did not track any single measure of growth-hormone secretion. The authors conclude that CJC-1295 raises basal and mean secretion while leaving the pulse pattern intact.

Study design

Healthy men aged 20 to 40 sampled every 20 minutes over 12 hours overnight, before and one week after a single injection of CJC-1295 at one of two doses.

What it does not show

Small physiological study of one injection with a one-week follow-up. Its subject is the shape of hormone secretion, not any clinical outcome.

A clinical trial tests a pharmaceutical form of a compound, in a defined patient group, under medical supervision, with a defined endpoint. None of that transfers to a research-grade vial, and this page does not suggest it does.

Where this paper is cited

  • CJC-1295 with DAC — Growth hormone remained pulsatile under CJC-1295: trough and mean levels rose while pulse frequency was unchanged.

Other papers cited for CJC-1295 with DAC

Further reading

How this page was made: the citation was retrieved from PubMed by PMID and checked against the title on the product page; the summary was written from the paper's abstract and reports only what the abstract reports. Read the paper itself before relying on any figure here.

Research use only This page summarises a published paper. It is not a claim that any product sold by Zyrna Research does what the paper describes, the trial used a pharmaceutical product under medical supervision, and nothing here is dosing guidance. Nothing sold by Zyrna Research is for human or veterinary use.